Accelerating Precision Medicine™

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer

What are Radioligands?

Improving cancer outcomes with Radioligand Therapies

POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. Radioligands offer improved efficacy and superior safety profiles versus platform chemotherapy agents and can provide patients and their families the very best possible outcomes.

Learn about POINT Biopharma

The Science of Radioligand Therapy

Although it may seem futuristic, radioligand therapy is a safe and proven treatment method for a variety of cancers.

First a scan is performed

Next the drug is administered

The drug then seeks out cancer

Learn about Radioligand Therapies

Our Treatment Pipeline

We are dedicated to expanding access to radiology therapies, making them applicable to more cancers, accessible to more people, and improving the lives of patients and their families. Here are the compounds we are currently developing:
Two people hugging

Help improve the lives of patients and their families

We are hiring for clinical, manufacturing and business roles:
Careers at POINT Biopharma

News

Announcing licensing and partnership for canSEEK™ pan-cancer targeting technology

POINT today announced that it has entered into a definitive agreement with Bach Biosciences, a company commercializing the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University...

POINT Biopharma Presents at 2020 BIO Investor Forum

POINT Biopharma Inc. announces its CEO Dr. Joe McCann will present at the 2020 BIOInvestor Forum.

POINT Biopharma Further Strengthens Executive Team with Key Clinical and Financial Members

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits...